Abstract
[Display omitted]
•Cutaneous melanoma (CM) is a multifactorial and heterogeneous disease.•Understanding CM molecular biology is crucial to design targeted nanomedicines.•Biomimetic nanovaccines may constitute future strategies for CM immunotherapy.•Magnetic nanosystems can be used as CM theranostic platforms.•Different advanced CM therapeutic modalities can be combined using nanosystems.
Cutaneous melanoma (CM) is a multifactorial disease whose treatment still presents challenges: the rapid progression to advanced CM, which leads to frequent recurrences even after surgical excision and, notably, the low response rates and resistance to the available therapies, particularly in the case of unresectable metastatic CM. Thereby, alternative innovative therapeutic approaches for CM continue to be searched.
In this review we discuss relevant preclinical research studies, and provide a broad-brush analysis of patents and clinical trials which involve the application of nanotechnology-based delivery systems in CM therapy.
Nanodelivery systems have been developed for the delivery of anticancer biomolecules to CM, which can be administered by different routes. Overall, nanosystems could promote technological advances in several therapeutic modalities and can be used in combinatorial therapies.
Nevertheless, the results of these preclinical studies have not been translated to clinical applications. Thus, concerted and collaborative research studies involving basic, applied, translational, and clinical scientists need to be performed to allow the development of effective and safe nanomedicines to treat CM.